MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the “Company”) (NYSE: PFLT) today announced that it has priced an underwritten public offering of $200 million aggregate principal amount of its 6.75% notes due 2029 (the “Notes”). The Notes will mature on March 4, 2029 and may be redeemed in whole or in part at the Company’s option at any time at par plus a “make-whole” premium, if applicable, provided that the Notes may be redeemed at par three months prior to their maturity. ...

Core Insights - Oppenheimer & Co. Inc. has appointed Vien Le as Managing Director in its Public Finance Investment Banking Group, based in Los Angeles [1][2] - Le brings over 20 years of municipal finance experience, focusing on California and supporting clients in the West, including Oregon and Washington [2][3] - The addition of Le is expected to enhance Oppenheimer's capabilities and momentum in the public finance sector on the West Coast [3][5] Company Overview - Oppenheimer Holdings Inc. provides a comprehensive range of wealth management, securities brokerage, and investment banking services to high-net-worth individuals, families, corporate executives, businesses, and institutions [5]

AMG National Trust Bank trimmed its holdings in shares of Barclays PLC (NYSE:BCS – Free Report) by 25.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,286 shares of the financial services provider’s stock after selling 26,421 shares during the period. AMG National Trust Bank’s holdings in Barclays were worth $1,639,000 at the end of the most recent reporting period. Get Barclays alerts: Several other large investors h ...

Core Viewpoint - Ondas Holdings Inc. has announced a $1 billion registered direct offering of common stock and pre-funded warrants, aimed at institutional investors, to support corporate development and strategic growth initiatives [1][3]. Offering Details - The offering consists of 19,000,000 shares of common stock and pre-funded warrants to purchase up to 41,790,274 shares, totaling 60,790,274 Common Stock Equivalents [1][2]. - Each share of common stock is priced at $16.45, while each pre-funded warrant is priced at $16.4499, representing a premium of approximately 17.5% over the closing stock price on January 8, 2026 [2]. - The offering is expected to close on or about January 12, 2026, pending customary closing conditions [2]. Financial Projections - Ondas anticipates gross proceeds of approximately $1 billion from the offering, with potential additional proceeds of about $3.4 billion if all common stock warrants are exercised [3]. - The net proceeds will be utilized for corporate development, including acquisitions, joint ventures, and investments [3]. Placement Agents - Oppenheimer & Co. Inc. is the lead placement agent for the offering, with several other firms acting as co-placement agents [4].

Core Insights - Oppenheimer & Co. Inc. has strengthened its Biotech Research Team by hiring Kostas Biliouris as Managing Director, enhancing its long-standing expertise in the biotech sector [1][3] - Biliouris brings extensive experience from BMO Capital Markets and Morgan Stanley, along with a Ph.D. in biochemical engineering, which will contribute to Oppenheimer's research capabilities in genetic medicines and biotech [2][3] - The firm aims to expand its research coverage in biotech, an area characterized by rapid innovation, to better serve its institutional and corporate clients [3][4] Company Overview - Oppenheimer & Co. Inc. is a subsidiary of Oppenheimer Holdings Inc., providing a comprehensive range of wealth management, securities brokerage, and investment banking services [4] - The healthcare franchise, including biotechnology, pharmaceuticals, and medical technology, has been a core area of expertise for Oppenheimer [3]

Core Insights - Apollon Wealth Management, based in Mount Pleasant, S.C., is set to acquire The Motley Fool's wealth management division, with the deal expected to close in 2026. Apollon currently manages over $8.65 billion in assets [1] - Motley Fool Wealth Management manages approximately $1.5 billion in client assets and has eight financial advisors along with 15 other employees. The firm was established in 2014 to leverage Motley Fool's retail investor base [2] - Post-acquisition, Apollon will enhance its offerings in financial planning, investments, and related wealth services, including estate planning. The division initially started as a robo-advisor but transitioned to providing human advisors for clients with assets of $300,000 or more [3] Company Details - The current leadership of Motley Fool Wealth Management includes Interim President Megan Brinsfield, who has been with the firm since 2014. The future role of Brinsfield post-acquisition remains unclear [4] - Oppenheimer & Co. Inc. served as the financial advisor for the acquisition, while Dechert LLP acted as legal counsel for Motley Fool Wealth Management. Merchant Investment Management holds a minority stake in Apollon [5]

Core Insights - Oppenheimer & Co. Inc. has hired Guy T. Logan as Managing Director, Head of Infrastructure & Mid-Atlantic Region in its Public Finance Investment Banking Division, indicating the firm's rapid expansion in this area [1][3] Group 1: New Hire and Experience - Guy T. Logan brings over 30 years of municipal finance experience, having been involved in more than 250 transactions totaling over $55 billion for various municipal issuer clients [2] - Logan's previous roles include senior municipal investment banker at Raymond James and 26 years at Citigroup Global Markets, where he held multiple leadership positions [4] Group 2: Strategic Growth - The addition of Logan is part of Oppenheimer's strategy to build a leading Public Finance platform, with the team growing through strategic hires under the guidance of Beth Coolidge [3][4] - Logan's notable past transactions include leading a $2.2 billion refinancing for Jefferson County, Alabama, and being a senior banker on a $2.9 billion bond issuance recognized as the National Deal of the Year in 2012 [5] Group 3: Cultural Fit and Vision - Logan expressed enthusiasm about joining Oppenheimer, highlighting the firm's momentum, collaborative culture, and commitment to exceptional outcomes for public-sector clients [6] - He has been actively involved in promoting diversity in the financial industry, serving on the Board of Directors of the National Association of Securities Professionals since 2012 [6]

Core Viewpoint - Nurix Therapeutics, Inc. successfully closed an underwritten registered offering of 24,485,799 shares at $10.21 per share, raising gross proceeds of $250 million to fund clinical development and research activities [1][4]. Group 1: Offering Details - The offering included participation from both new and existing investors, highlighting strong support for the company's mission [2]. - J.P. Morgan Securities LLC, Jefferies LLC, and Stifel, Nicolaus & Company acted as joint book-running managers for the offering [3]. - The securities were offered under a shelf registration statement previously filed with the SEC [5]. Group 2: Use of Proceeds - The net proceeds will primarily fund the clinical development of bexobrutideg (NX-5948) for chronic lymphocytic leukemia (CLL) and explore potential autoimmune indications [4]. - Additional funds will support research and development activities to expand the pipeline and cover working capital and general corporate purposes [4]. Group 3: Company Overview - Nurix Therapeutics focuses on targeted protein degradation medicines for oncology and autoimmune diseases, with a pipeline that includes degraders of Bruton's tyrosine kinase (BTK) [8][9]. - The company is advancing multiple potentially first-in-class or best-in-class drug candidates and has collaborations with major pharmaceutical companies like Sanofi and Gilead [8][9].

Core Viewpoint - Nurix Therapeutics, Inc. has announced the pricing of its underwritten registered offering of 24,485,799 shares at $10.21 per share, aiming to raise approximately $250 million for clinical development and research activities [1][4]. Group 1: Offering Details - The offering consists of 24,485,799 shares priced at $10.21 each, with expected gross proceeds of $250 million before expenses [1]. - The offering is set to close on or about October 23, 2025, pending customary closing conditions [1]. - Participation in the offering includes both new and existing investors such as General Atlantic and Redmile Group [2]. Group 2: Use of Proceeds - Nurix intends to use the net proceeds primarily for clinical development of drug candidates, including bexobrutideg (NX-5948) for chronic lymphocytic leukemia (CLL) and potential autoimmune indications [4]. - Additional uses include funding research and development to expand the pipeline, as well as for working capital and general corporate purposes [4]. Group 3: Management and Registration - J.P. Morgan Securities LLC, Jefferies LLC, and Stifel, Nicolaus & Company are acting as joint book-running managers for the offering [3]. - The offering is made under a shelf registration statement previously filed with the SEC, which was declared effective on June 11, 2024 [5].

Core Viewpoint - Immuneering Corporation has announced a proposed underwritten public offering of its Class A common stock and a concurrent private placement with Sanofi for $25 million, aimed at advancing its oncology product candidates and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes shares of Class A common stock and pre-funded warrants, with underwriters granted a 30-day option to purchase an additional 15% of the offered shares [1]. - Sanofi will purchase $25 million worth of Immuneering's Class A common stock or non-voting Class B common stock at the public offering price, in a private placement expected to close concurrently with the public offering [1][2]. - The offering is subject to market conditions and the private placement is contingent upon the closing of the public offering [1]. Group 2: Use of Proceeds - The net proceeds from both the public offering and private placement will be utilized to advance preclinical and clinical development of product candidates, as well as for working capital and other general corporate purposes [2]. Group 3: Regulatory Information - The offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on August 20, 2025 [3]. - A preliminary prospectus supplement will be filed with the SEC, and copies will be available through the underwriters [3][7]. Group 4: Securities Registration - The shares sold in the private placement will not be registered under the Securities Act of 1933 and cannot be offered or sold in the U.S. without registration or an applicable exemption [4].